Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
A barbiturate that is effective as a hypnotic and sedative.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Hydrocodone | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Magnesium sulfate | The therapeutic efficacy of Hexobarbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Hexobarbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Mirtazapine | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Orphenadrine | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Pramipexole | Hexobarbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Hexobarbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Hexobarbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Hexobarbital. |
| Suvorexant | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Thalidomide | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Hexobarbital can be decreased when it is combined with Dabrafenib. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Hexobarbital. |
| Luliconazole | The serum concentration of Hexobarbital can be increased when it is combined with Luliconazole. |
| Mefloquine | The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Mefloquine. |
| Orlistat | Orlistat can cause a decrease in the absorption of Hexobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Hexobarbital. |
| Propacetamol | The metabolism of Propacetamol can be increased when combined with Hexobarbital. |
| Chloramphenicol | The metabolism of Hexobarbital can be decreased when combined with Chloramphenicol. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Hexobarbital. |
| Felbamate | The serum concentration of Hexobarbital can be increased when it is combined with Felbamate. |
| Griseofulvin | The serum concentration of Griseofulvin can be decreased when it is combined with Hexobarbital. |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital. |
| Mianserin | The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Mianserin. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital. |
| Pyridoxine | The metabolism of Hexobarbital can be increased when combined with Pyridoxine. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Hexobarbital. |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Hexobarbital. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Hexobarbital. |
| Topotecan | Hexobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital. |
| Sodium oxybate | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Hexobarbital. |
| Aminophylline | The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Aminophylline. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum toxin type B. |
| Meperidine | Hexobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine. |
| Somatostatin | The risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital. |
| Ethanol | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital. |
| Citalopram | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Sibutramine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Alaproclate. |
| Nefazodone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Milnacipran. |
| Naltrexone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Bezitramide. |
| Morphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Hydromorphone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Sufentanil. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Hexobarbital is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Opium. |